Dysarthria
Dysarthria encompasses a collective group of motor speech disorders stemming from abnormalities in the strength, speed, range, steadiness, tone, or accuracy of movements required for the control of the respiratory, phonatory, resonatory, articulatory, and prosodic aspects of speech production. The primary cause is damage to the brain or nerves that control the muscles involved in speech.
Characteristics of Dysarthria
Dysarthria is marked by a variety of speech changes, which can be mild to severe, depending on the extent and location of the neurological impairment. Changes can include slurred or slow speech, limited tongue, lip, and jaw movement, abnormal intonation, changes in voice quality, and difficulty maintaining regular speech volume.
Underlying Causes and Classifications
Dysarthria can result from neurological conditions that affect the motor control of speech muscles. These may include stroke, brain injury, Parkinson's disease, Amyotrophic lateral sclerosis (ALS), Multiple sclerosis, Huntington's disease, and Cerebral palsy.
Dysarthrias are typically classified based on the primary location of neurological damage, such as flaccid dysarthria (lower motor neuron damage), spastic dysarthria (upper motor neuron damage), ataxic dysarthria (cerebellar damage), and hypokinetic or hyperkinetic dysarthria (basal ganglia damage).
Diagnosis and Management
The diagnosis of dysarthria involves a thorough medical history, neurological examination, and specific speech and language assessments. These evaluations help identify the type of dysarthria and develop an appropriate treatment plan.
Management often involves speech and language therapy. Techniques can include exercises to improve speech muscle strength and coordination, breath control techniques, and strategies to make speech clearer, such as speaking slowly or in a louder voice.
References
<references/>
- "Dysarthria." American Speech-Language-Hearing Association. [1]
- "Dysarthria as a result of neurological injury." NeuroRehabilitation. [2]
- "Clinical characteristics and management of dysarthria." Journal of Neurology, Neurosurgery & Psychiatry. [3]
- "Current therapeutic options for dysarthria." Cochrane Database of Systematic Reviews. [4]
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa

Tired of being overweight?
Get started with evidence based, physician-supervised
affordable GLP-1 weight loss injections
Now available in New York City and Philadelphia:
- Semaglutide starting from $59.99/week and up
- Tirzepatide starting from $69.99/week and up (dose dependent)
✔ Evidence-based medical weight loss ✔ Insurance-friendly visits available ✔ Same-week appointments, evenings & weekends
Learn more:
Start your transformation today with W8MD weight loss centers.
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian


